Loading clinical trials...
Loading clinical trials...
Phase ib/II Trial of Copanlisib, a Selective PI3K Inhibitor, in Combination With Cetuximab in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss.
Conditions
Interventions
Copanlisib
Cetuximab
Locations
7
France
Institut de Cancérologie de l'Ouest
Angers, France
Centre Georges François Leclerc
Dijon, France
Centre Oscar Lambret
Lille, France
Centre Léon Bérard
Lyon, France
Institut de Cancérologie de Lorraine
Nancy, France
Centre Antoine Lacassagne
Nice, France
Start Date
June 1, 2016
Primary Completion Date
October 9, 2019
Completion Date
October 9, 2019
Last Updated
March 29, 2021
NCT03485209
NCT02296684
NCT03509012
NCT02383966
NCT02585973
NCT02658214
Lead Sponsor
UNICANCER
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions